Madison Muller

Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro won US approval to reduce the risk of serious cardiovascular problems, broadening the medicine’s reach beyond controlling blood sugar and strengthening its position in the increasingly competitive market for GLP-1 drugs.

A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and strokes in a final-stage trial, marking a major setback for a new approach to prevent cardiovascular disease.

A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and ... Your free access has ended.

A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and strokes in a final-stage trial, marking a major setback for a new approach to prevent cardiovascular disease.

A Novartis AG drug billed as a potential blockbuster failed to reduce the risk of heart attacks and strokes in a final-stage trial, marking a major setback for a new approach to prevent cardiovascular disease.

An experimental weight-loss pill from Structure Therapeutics Inc. helped patients lose as much as 16% of their body weight, suggesting it may one day compete with rivals from Eli Lilly & Co. and Novo Nordisk A/S.

Bloomberg journalists answer your questions about the future of cancer treatment in a Live Q&A on Friday, Sept. 11 at 11 a.m. EDT

El rápido auge de los medicamentos para bajar de peso está moldeando la forma en que la Generación Alfa y los más jóvenes de la Generación Z entienden la salud y la imagen corporal, y deja a algunos expuestos a problemas que podrían acompañarlos de por vida.

AstraZeneca Plc’s breast cancer pill failed to delay disease progression more than the standard treatment in a late-stage trial, results that could dampen optimism around the medicine.

AstraZeneca Plc's breast cancer pill failed to delay disease progression more than the standard treatment in a late-stage trial, results that could dampen optimism around the medicine.